rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Exagen Inc.

XGN · Nasdaq

Health CareDiagnostics & LabsLeading

XGN stood above a rising 150-day average in 13 of the last 52 weekly readings, including each of the last 9 weeks. It is 48.8% above that average now. Diagnostics & Labs: 48% of its 44 stocks in an uptrend (−2 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
9 in a row
Industry in uptrend
48% -2 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$505K
Officials’ trades on record
0
Institutions holding
54 (-4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 13 of 52 weeks.

17 Apr – 16 Oct
20%38%55%Apr 26Jun 26Jul 26Sep 26Oct 26

Diagnostics & Labs: About half its stocks are in an uptrend and the share has held steady. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1.1M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months4
Buyers · sellers0 · 2
WhoDidSharesTraded
Jeffrey G. BlackChief Financial Officersold20,614at $7.221 Sep 2026filed 2 Sep 2026
John AballiPresident and CEOsold15,698at $3.623 Mar 2026filed 4 Mar 2026
Jeffrey G. BlackChief Financial Officersold1,584at $3.6124 Feb 2026filed 25 Feb 2026
John AballiPresident and CEOsold11,430at $3.6124 Feb 2026filed 25 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders54-4 on the quarter
New · exited8 · 12
Reported value$34.4M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
WEXFORD CAPITAL LPunchanged · filed 14 Aug 2026792,855$3.7M00.0%
NANO CAP NEW MILLENNIUM GROWTH FUND L Padded · filed 14 Aug 2026675,000$3.1M+90,000+15.4%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026612,832$2.8M-65,820−9.7%
FourWorld Capital Management LLCadded · filed 14 Aug 2026596,528$2.8M+156,578+35.6%
SILVERCREST ASSET MANAGEMENT GROUP LLCreduced · filed 14 Aug 2026514,761$2.4M-23,109−4.3%
KENNEDY CAPITAL MANAGEMENT LLCreduced · filed 14 Aug 2026485,048$2.3M-8,612−1.7%
Mink Brook Asset Management LLCadded · filed 14 Aug 2026475,944$2.2M+106,917+29.0%
JANE STREET GROUP, LLCadded · filed 14 Aug 2026322,502$1.5M+85,767+36.2%
First Eagle Investment Management, LLCadded · filed 5 Aug 2026306,965$1.4M+181,723+145.1%
MARSHALL WACE, LLPadded · filed 13 Aug 2026306,703$1.4M+279,414+1023.9%
31 Mar 2023 – 30 Jun 2026
255074Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Jeffrey G. Black Company insiderChief Financial Officer · last 1 Sep 20261 · 3
Bruce C. Robertson Company insiderDirector · last 9 Jun 20260 · 0
Chas McKhann Company insiderDirector · last 9 Jun 20260 · 0
Frank Stokes Company insiderDirector · last 9 Jun 20260 · 0
Paul Kim Company insiderDirector · last 9 Jun 20260 · 0
Scott D. Kahn Company insiderDirector · last 9 Jun 20260 · 0
John Aballi Company insiderPresident and CEO · last 12 Mar 20263 · 4
Ana Hooker Company insiderDirector · last 10 Jun 20250 · 0
Tina Susan Nova Company insiderDirector · last 10 Jun 20250 · 0
Nmsic Co-Investment Fund, L.p. Company insider10% owner · last 25 Mar 20250 · 3
Sun Mountain Capital Partners Llc Company insider10% owner · last 20 Nov 20240 · 1
Kamal Adawi Company insiderCFO and Corporate Secretary · last 4 Mar 20240 · 4

Same industry

CDNA CareDxLeading+83%
NTRA NateraLeading+46%
PSNL PersonalisLeading+35%
BDSX BiodesixLeading+19%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202558.3%
Operating profit marginFY 2025 · to 31 Dec 2025-21.1%
Free cash flow marginFY 2025 · to 31 Dec 2025-21.4%
Return on capital employedFY 2025 · to 31 Dec 2025-32.1%
Debt to equityFY 2025 · to 31 Dec 20251.35×
Research spendFY 2025 · to 31 Dec 20259.4%
Share count trendFY 2025 · to 6 Mar 20265.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$32.2M
Free cash flowFY 2025 · to 31 Dec 2025−$14.3M

Analyst forecasts

No analyst forecasts yet.